2026-01-20
33Recently, Eli Lilly delivered a stunning performance with tirzepatide, with annual sales exceeding $36.5 billion, claiming the crown of "global blockbuster drug." Behind this trillion-dollar market valuation lies the absolute dominance of GLP-1 peptide drugs!
From glucose control and weight management to anti-aging applications, peptide drugs are experiencing explosive growth, driven by their broad indications and high safety profiles. An era belonging to peptides has truly arrived.
Today, the results of the "2025 Peptide Industry Annual Popularity TOP List," jointly initiated by E-Pharmacy Academy and Yaodu, were officially announced. After nearly a month of online voting and industry-wide attention, Jiangsu JV Bio-Equipment Co., Ltd. (hereinafter referred to as "JV Bio") successfully made the list and received this prestigious honor, thanks to its outstanding brand influence, solid technical strength, and the high recognition from its customers and peers!
This honor is a strong affirmation of JV Bio's deep commitment to the peptide equipment sector and its continuous empowerment of industry development.
The "2025 Peptide Industry Annual Popularity TOP List" is designed to provide strong support for the global peptide industry's development and to enhance the industry's R&D capabilities and brand influence. Since its launch on January 14, 2026, the selection has attracted numerous outstanding enterprises to participate, with unprecedented online voting enthusiasm, fully reflecting the industry's keen interest in the peptide track.
JV Bio's successful inclusion on the list is not only a testament to the trust of our customers and partners, but also a reflection of the company's years of deep cultivation and accumulated expertise in the peptide equipment field.
From the $36.5 billion blockbuster story of tirzepatide to the explosive growth of global peptide drug R&D pipelines, one indisputable reality stands out: the peptide drug boom is inseparable from full-process equipment support—from laboratory to industrialization.
A stable and efficient equipment system is the critical link that ensures process implementation and enables scale-up breakthroughs. JV Bio has always focused on the peptide drug track, adhering to the philosophy of "full-process equipment innovation from laboratory to industrialization." With deep technical accumulation and continuous product iteration, we provide solid equipment support for the peptide industry, committed to empowering breakthroughs across the entire peptide chain with卓越 equipment, and helping customers seize the initiative in fierce market competition.
Looking ahead, JV Bio will continue to deepen its presence in the peptide equipment field, delivering better products and more comprehensive services to help China's peptide industry reach new heights. We look forward to joining hands with industry peers to jointly promote the innovation and application of peptide technology, and to contribute "JV Bio strength" to global healthcare!
